Global Emphysema Market, By Type (Centriacinar, Panacinar, Paraseptal, Others), Diagnosis (Imaging Test, Lab Test, Spirometry, Others), Complications (Chest Infections, Collapsed Lung (Pneumothorax), Heart Problems, Lungs Hole (bullae), Others), Treatment (Medication, Therapy, Surgery, Others), Route of Administration (Oral, Parenteral, Inhalation, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Emphysema Market Analysis and Size
The global emphysema market is expected to witness significant growth during the forecast period. Growing cases of air pollution related allergies drives the emphysema market. Due to increased smoking & marijuana smoking, increased air pollution and presence of chronic lung diseases also boost the emphysema market growth. Medical advancements which involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global emphysema market in the forecast period 2022-2029. The expected CAGR of global emphysema market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Emphysema is characterized by respiratory diseases. In these condition lungs tiny air sac called as alveoli stretch out of shape and ruptured as a result these rupture alveoli become destroyed, damaged and lose their elasticity. Over time, the inner lining of the alveoli becomes weak and causes air to stay trapped inside the lungs because the damaged lung sacs can't empty. It is a progressive condition and worsens over time, due to this lung lose their ability to absorb oxygen and release carbon dioxide, and breathing becomes difficult. Emphysema and chronic bronchitis are two common form of COPD and often occur together. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Centriacinar, Panacinar, Paraseptal, Others), Diagnosis (Imaging Test, Lab Test, Spirometry, Others), Complications (Chest Infections, Collapsed Lung (Pneumothorax), Heart Problems, Lungs Hole (bullae), Others), Treatment (Medication, Therapy, Surgery, Others), Route of Administration (Oral, Parenteral, Inhalation, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Intersect ENT, Inc (U.S.)
|
|
Market Opportunities
|
|
Global Emphysema Market Dynamics
Drivers
- More Product Launches
Governments of several countries are conducting awareness programs to educate more number of people about the availability of emphysema treatment and diagnosis options. There has been numerous products that contain better capabilities that has been launched by major market players. Olympus announced the launch of FDA approved spiration valve system in January 2021 which provides a minimally invasive treatment substitute for eligible patients.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Incidence of Cigarette Smoking
Cigarette smoking is one of the major reasons for emphysema. As per the reports of the American Lung Association (ALA), cigarette smoking alone caused approximately 85–90% of all chronic obstructive pulmonary diseases (COPDs). It leads to weakening of lungs. Hence, this creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global emphysema market over a forecast period.
- Increasing Cost of Treatment Therapeutics
Even though the disease prevalence is increasing, but along with it, the drug costs are also increasing. These rising treatment costs are restraining the market growth.
This global emphysema market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global emphysema market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Emphysema Market
The outbreak of the COVID-19 pandemic impacted the worldwide economy. According to the Centers for Disease Control and Prevention, people with COPD, mainly emphysema and chronic bronchitis (CDC), are at much higher risk of getting a severe disease from COVID-19. Thus, the global emphysema market observed much growth during and after the COVID-19 pandemic.
Global Emphysema Market Scope
The global emphysema market is segmented on the basis of type, complications, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Centriacinar
- Panacinar
- Paraseptal
- Others
Complications
- Chest Infections
- Collapsed Lung
- Heart Problems
- Lungs Hole
- Others
Diagnosis
- Imaging Test
- Lab Test
- Spirometry
- Others
Treatment
- Medication
- Therapy
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Emphysema Market Regional Analysis/Insights
The global emphysema market is analysed and market size insights and trends are provided by type, complications, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global emphysema market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increased prevalence of lungs disorders such as asthma, COPD and presence of key manufacture of the product.
Asia-Pacific dominates the market due to increased government and awareness programs, increased population with tobacco smoking and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Emphysema Market Share Analysis
The global emphysema market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global emphysema market.
Key players operating in the global emphysema market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Intersect ENT, Inc (U.S.)
SKU-